Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease

This study was supported by the Canadian Institutes of Health Research (DRA 201210 - PA: Drug Safety and Effectiveness; www.cihr-irsc.gc.ca), Fulbright Canada (www.fulbright.ca), the McLaughlin Centre for Population Health Risk Assessment (www.mclaughlincentre.ca), the Cerner Corporation (http://www.cerner.com), and Risk Sciences International (www.risksciences.com). The Cerner Corporation and Risk Sciences International are commercial companies. The funders provided support in the form of salaries for authors [J.A.G.C., Y.F., H.D.H., D.S.M., and D.R.M.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.